Fig. 2
From: A novel quinoline with airway relaxant effects and anti-inflammatory properties
The effect of RCD405 treatment on body weight, lung weight, IgE levels and airway hyperresponsiveness. A Experimental setup of the OVA-induced allergic airway inflammation model. Mice were divided into the following experimental groups: Veh/PBS (n = 8), RCD405/PBS (n = 8), Veh/OVA (n = 8), RCD405/OVA (n = 8), and BUD/OVA (n = 8). Each mouse received an intraperitoneal injection of 20 μg OVA in alum (1:10) at day 0 and 7. Intratracheal challenges with 35 μg OVA were performed at day 14, 16, 18 and 20 in the Veh/OVA, RCD405/OVA, and BUD/OVA groups. Mice were treated with RCD405 (10 mg/kg) or budesonide (3 mg/kg) intratracheally 1 h before each challenge. B Mouse weights on day 21 shown as percentage of starting weight. C Lung weights on day 21. D Total IgE and (E) OVA-specific IgE levels measured by ELISA in plasma from Veh/PBS, RCD405/PBS, Veh/OVA, RCD405/OVA, and BUD/OVA treated mice. Using a flexiVent, several different parameters were measured: (F) Rrs, dynamic resistance, assessing the level of constriction in the lungs, (G) Ers, elastance, representing the stiffness of the respiratory system, (H) Rn, Newtonian resistance, representing the resistance of conducting airways, (I) G, tissue damping, reflecting tissue resistance, and (J) H, tissue elastance. Experimental groups: Veh/PBS (n = 10), RCD405/PBS (n = 10), Veh/OVA (n = 9) and RCD405/OVA (n = 7). Statistical comparisons were made using one-way ANOVA or Two-way ANOVA followed by Šídák's multiple comparisons test (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 and ****P ≤ 0.0001, Veh/OVA vs Veh/PBS and RCD405/PBS groups. ##P ≤ 0.01, ###P ≤ 0.001, and ####P ≤ 0.0001, Veh/OVA vs RCD405/OVA)